特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性腎疾患 (CKD) 治療薬の世界市場:将来予測

Chronic Kidney Disease Drugs Market - Global Forecast to 2026

発行 Coherent Market Insights 商品コード 664179
出版日 ページ情報 英文 178 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.27円で換算しております。
慢性腎疾患 (CKD) 治療薬の世界市場:将来予測 Chronic Kidney Disease Drugs Market - Global Forecast to 2026
出版日: 2018年06月04日 ページ情報: 英文 178 Pages
概要

当レポートでは、世界の慢性腎臓病 (CKD) 治療薬の市場について分析し、市場の基本構造や背景事情 (疾患概要、主な治療法、規制情報など)、主な市場促進・抑制要因、全体的な市場規模の動向見通し (今後10年間分)、薬剤クラス別・流通チャネル別・地域別の詳細動向、主要企業のプロファイルと業績、今後の市場の方向性などを調査しております。

第1章 分析目的と前提条件

第2章 市場概略

  • 分析概略
  • エグゼクティブ・サマリー
  • COM (Coherent Opportunity Map:市場機会マップ)

第3章 市場のダイナミクス・規制・動向の分析

  • 市場のダイナミクス
    • 促進要因
    • 抑制要因
    • 市場機会
  • 市場影響度の分析
  • PEST分析
  • ポーターのファイブフォース分析
  • 規制シナリオ

第4章 世界の慢性腎疾患 (CKD) 治療薬の市場:薬剤クラス別

  • イントロダクション
    • 市場シェア分析 (最新値・予測値)
    • 年間成長率の分析 (今後10年間分)
    • 部門別分析
  • ACE Inhibitors
    • イントロダクション
    • 市場規模とその予測、年間成長率 (金額ベース、今後11年間分)
  • B-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Erythropoiesis-Stimulating Agents (ESA)
  • その他

第5章 世界の慢性腎疾患 (CKD) 治療薬の市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • eコマース

第6章 世界の慢性腎疾患 (CKD) 治療薬の市場:地域別

  • イントロダクション
  • 北米市場 (米国、カナダ)
    • 市場規模とその予測、薬剤クラス別 (金額ベース、今後11年間分)
    • 市場規模とその予測、流通チャネル別 (金額ベース、今後11年間分)
    • 市場規模とその予測、国別 (金額ベース、今後11年間分)
  • 欧州市場 (英国、ドイツ、イタリア、フランス、スペイン、ロシアなど)
  • アジア太平洋地域市場 (中国、インド、日本、ASEAN諸国、オーストラリア、韓国など)
  • ラテンアメリカ市場 (ブラジル、メキシコ、アルゼンチンなど)
  • アフリカ市場 (中部アフリカ、南アフリカ、北部アフリカ)
  • 中東市場 (湾岸協力会議 (GCC) 諸国、イスラエルなど)

第7章 競争環境

  • 企業プロファイル
    • Amgen, Inc.
      • 企業概要
      • 製品ポートフォリオ
      • 近年の主な動向
      • 財務実績
      • 市場戦略
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • AstraZeneca Plc
    • F. Hoffman La Roche Ltd.
    • Sanofi S.A.
    • キッセイ薬品工業
    • AbbVie, Inc.
    • GlaxoSmithKline Plc
    • Keryx Biopharmaceuticals, Inc.

第8章 付録

目次

Chronic kidney disease can be controlled and prevented from worsening with the help of kidney friendly diet plans and efficiently managing other diseases, which may lead to chronic kidney diseases. For instance, facts such as maintaining a healthy blood pressure, having a low-salt and low-fat diet, control blood sugar, regular exercise, and avoiding smoking and drinking may prevent chronic kidney disease from worsening. Another form of kidney disease is acute kidney disease, which occurs directly due to disorders affecting kidney such as inadequate blood supply and improper urine flow from kidneys. Apart from medication management, other treatment options for end stage renal diseases include dialysis and kidney transplant.

Market Dynamics

The global chronic kidney disease drugs market is driven by factors such as increasing prevalence of chronic kidney disease and high presence of generic drug manufacturers in the market. According to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. Individual government organizations and manufactures are indulged in research and development as well as increasing awareness about chronic kidney diseases, which is fostering growth of the chronic kidney disease drugs market. In March 2018, the Indian Medical Association (IMA) launched chronic kidney disease prevention project to control the epidemic of chronic kidney disease. Continuous requirement of medication coupled with easy availability of drugs is expected to boost growth of chronic kidney disease drugs market over the forecast period. However, absence of novel treatment option and delay in diagnosis of the disease due to vague symptoms are expected to hinder growth of the chronic kidney disease drugs market.

Key features of the study:

  • This report provides in-depth analysis of chronic kidney disease drugs market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic kidney disease drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the chronic kidney disease drugs market

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
    • ACE Inhibitors
    • B-Blockers
    • Calcium Channel Blockers
    • Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • ACE Inhibitors
      • B-Blockers
      • Calcium Channel Blockers
      • Diuretics
      • Erythropoiesis-Stimulating Agents (ESAs)
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • Amgen, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • AstraZeneca Plc
    • F. Hoffmann La Roche Ltd.
    • Sanofi S.A.
    • Kissei Pharmaceutical Co. Ltd.
    • AbbVie Inc.
    • GlaxoSmithKline Plc
    • Keryx Biopharmaceuticals, Inc.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • PORTER's Analysis
  • Regulatory Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • ACE Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • B-Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Calcium Channel Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Diuretics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Erythropoiesis-Stimulating Agents (ESAs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

5. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2016-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Chronic Kidney Disease Drugs Market, By Regions, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Company Profiles
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffman La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Kissei Pharmaceutical Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Keryx Biopharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact